Company Insights

GELS customer relationships

Explore interactive graphBrowse insights index
GELS customer relationship map

Gelteq (GELS) — Customer relationships that drive commercialization of a gel-based delivery platform

Gelteq monetizes proprietary gel delivery formulations by licensing and selling finished nutritional and cannabinoid products, plus supporting warehousing and fulfilment for partners that commercialize those products in key markets. Revenue today is concentrated, contract-driven and tied to a small number of commercial partners that are executing market launches in North America and Asia, making short-term cash flow growth highly dependent on a handful of distribution and manufacturing arrangements. For a deeper look at counterparties and commercial exposure visit https://nullexposure.com/.

Why these customer ties matter to equity investors

Gelteq is an early commercial-stage healthcare small cap: low revenue, negative EBITDA and concentrated shareholder and customer bases. Its valuation and near-term upside hinge on converting pilot customers into recurring, scaled orders and translating intellectual property into manufacturing and distribution agreements that commit minimum volumes. The customer relationships documented below are the proximate evidence of that conversion process.

Who Gelteq is selling to — relationship-by-relationship rundown

Shenzhen Mana Health Management Co. Ltd.

Gelteq signed a three-year sales agreement with Shenzhen Mana to distribute Gelteq-formulated consumer nutritional products in China, positioning Mana as the company’s distributor for the market. According to a StockTwits news item dated March 9, 2026, the agreement establishes a China-facing channel for consumer products built on Gelteq’s proprietary gels (https://stocktwits.com/news-articles/business/others/gelteq-signs-three-year-sales-agreement-with-shenzhen-mana-health-management-co-strengthening-gelteq-s-nutritional-product-expansion-into-china/cLIxLi8REnr). An additional news summary cited a minimum annual order commitment of roughly $1.3 million under the Mana arrangement, further anchoring near-term revenue expectations (Intellectia report, March 2026 — https://intellectia.ai/news/stock/gelteq-ltd-reports-22-bioavailability-increase-in-cannabinoid-oral-gel-shares-surge-501).

Healthy Extracts / Health Extracts, Inc. (HYEX)

Healthy Extracts is a named commercial partner driving Gelteq’s North American entry and product launches; Gelteq’s gel tech powers Healthy Extracts’ Hydrate EZ™ and Mynus Sugar™ products and the firms have moved from warehousing/fulfilment into broader manufacturing and distribution collaboration. Multiple published items document Healthy Extracts’ prior purchases, a warehousing/fulfilment foundation in the U.S., and a subsequent strategic manufacturing and commercial partnership announced in early 2026 (Yahoo Finance, March 2026 — https://finance.yahoo.com/news/gelteq-technology-powers-u-product-113000331.html; GlobeNewswire/ManilaTimes, February 11, 2026 — https://www.manilatimes.net/2026/02/11/tmt-newswire/globenewswire/gelteq-and-healthy-extracts-to-expand-gel-based-nutrition-technologies-with-new-strategic-manufacturing-commercial-partnership/2276281). A market report also describes incremental orders from Healthy Extracts and the use of Gelteq formulations in early U.S. SKUs (StocksToTrade summary, 2025/26 coverage — https://stockstotrade.com/news/gelteqlimited-gels-news-2025_09_06/; Mugglehead overview referencing HYEX orders — https://mugglehead.com/oral-drug-and-nutrient-delivery-specialist-soars-after-top-client-bumps-up-order-by-50/).

Whitney Johns Nutrition

Whitney Johns Nutrition uses Gelteq’s patented gel technology in its BRAIN ACTIVATE cognitive supplement product, giving Gelteq exposure to niche branded supplement lines and influencer-led channels. The relationship is documented in industry press that profiles increased customer orders and the product application of Gelteq’s formulation (Mugglehead, FY2024 coverage — https://mugglehead.com/oral-drug-and-nutrient-delivery-specialist-soars-after-top-client-bumps-up-order-by-50/).

How the contracts read and what that implies for Gelteq’s operating posture

Gelteq’s commercial model is contract-first: distribution agreements, purchase commitments and fulfilment arrangements form the core of revenue generation rather than open licensing alone. The public reporting of a three-year sales agreement with China distribution and the cited minimum annual order language are evidence of short- to medium-term revenue visibility when partners execute. At the same time, Gelteq’s overall financial profile — small market cap, limited revenue base and negative operating margins — signals that customer concentration and execution risk are the predominant investment risks.

  • Contracting posture: The company operates on multi-year distribution and commercial supply agreements rather than one-off sales; this binds product rollouts to partner go-to-market execution.
  • Concentration: A handful of customers (Healthy Extracts, Shenzhen Mana, Whitney Johns Nutrition) dominate commercial progress; growth is therefore lumpy and customer-dependent.
  • Criticality: Gelteq’s gel formulation is presented as a product differentiator for partners’ SKUs, making the technology operationally critical for those branded launches.
  • Maturity: The company remains early-stage in commercial maturity — modest TTM revenue and negative margins — so partnerships are still in the conversion phase from trials and pilot orders to scaled supply.

For investors focused on counterparties and execution, these are the operative signals when assessing downside and upside.

Investment implications — upside drivers and the immediate risk checklist

The primary upside is straightforward: convert pilot and limited-commitment orders into recurring, scaled manufacturing contracts and broaden distribution outside initial channel partners. Healthy Extracts and Shenzhen Mana provide two levers — North America and China — that could materially lift revenue if minimums and growth triggers are realized. Conversely, the principal near-term risk is counterparty execution failure or order concentration, which would expose Gelteq’s small revenue base to volatility.

  • Key upside: Repeat orders and scale manufacturing with Healthy Extracts; expansion in China via Shenzhen Mana’s distribution network.
  • Key risk: High customer concentration and low institutional ownership increase volatility and reduce liquidity.

If you want a structured counterparty map and monitoring plan for GELS customers, review our coverage and tracking tools at https://nullexposure.com/ — they are designed for investment and operational due diligence.

What to watch next (catalysts and red flags)

Watch three things on the company’s timetable: (1) published quarterly revenue breakdowns showing recurring sales to Healthy Extracts or Mana, (2) any announced minimum-volume fulfilment milestones or manufacturing scale-up confirmations, and (3) updates on product launches tied to Whitney Johns Nutrition and other influencer-led channels. Absence of volume conversion or delays in fulfilment would be immediate red flags.

For direct access to continuous counterparty intelligence and event-driven alerts on GELS, see https://nullexposure.com/.

Bottom line

Gelteq’s commercial progress is real but fragile: named partners validate the product-market fit for Gelteq’s gel delivery technology, but the company’s financial scale and concentrated customer base mean execution on those partnerships is the decisive factor for investor returns. Monitor partner order flows, contract minimums and manufacturing scale announcements as the primary value inflection points.